TNDM — Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: Achieved $247 million in sales, a record for Q1, with U.S. sales of $161 million (up 7% year-over-year) and international sales of $86 million (up 3% year-over-year).
• Pump Shipments: Over 29,000 pumps shipped globally, with more than 19,000 in the U.S., reflecting approximately 10% year-over-year growth.
• Gross Margin: Improved to 55%, up nearly five percentage points year-over-year, marking the highest first-quarter gross margin in company history.
• Adjusted EBITDA: Approximately 1% of sales, a significant improvement from prior periods.
• Free Cash Flow: Generated $5 million in free cash flow, a notable change from typical cash burn in Q1.
• Cash Position: Ended the quarter with $570 million in total cash and investments.

2. Strategic Updates and Business Highlights

• Commercial Operations Modernization: Launched direct operations in the UK, Switzerland, and Austria, enhancing customer engagement and operational efficiency.
• Pay-as-You-Go (PayGo) Model: Transitioning to a multichannel strategy with PayGo in the pharmacy channel, achieving approximately 40% formulary coverage. Initial adoption is underway, with less than 5% of customers ordering through this channel.
• New Product Launches:
  • Tandem Mobi is now available for Android users.
  • FDA clearance received for Control-IQ+ for pregnant women with type 1 diabetes, making Tandem’s systems the first approved for this use.
  • Preparing for international launch of Abbott’s FreeStyle Libre 3+ integration and Mobi Tubeless submission to the FDA.

3. Forward Guidance and Outlook

• 2026 Guidance: Reaffirmed annual sales guidance of $1.065 billion to $1.085 billion, with U.S. sales projected between $730 million to $745 million and international sales between $335 million to $340 million.
• Q2 Expectations: Anticipating approximately $255 million in worldwide sales, with gross margins expected to remain consistent with Q1 levels (56%-57%).

4. Bad News, Challenges, or Points of Concern

• Infusion Set Supply Shortages: Ongoing capacity issues with a key supplier are impacting both U.S. and international sales, with expectations of continued modest disruptions into Q2.
• Transition to PayGo: Early adoption has been slower than anticipated, with only 6% of U.S. sales coming from pharmacy sales, indicating a need for improved operational efficiencies and customer education.
• Competitive Pressures: The market remains competitive, with concerns about potential share loss due to recalls and adverse events from competitors.

5. Notable Q&A Insights

• Market Dynamics: Management noted that the diabetes market remains large and underpenetrated, with optimism about growth driven by new technologies and business model changes.
• International Performance: Currency fluctuations positively impacted international sales, but a one-time accounting benefit in Switzerland inflated Q1 results.
• New Starts: New starts were down slightly year-over-year and sequentially, but management expects growth to resume as new product launches gain traction.
• Pharmacy Transition: The transition to pharmacy sales is complex, requiring new prescriptions and physician engagement, but management is optimistic about long-term benefits.
• Mobi Tubeless Launch: Expected to enhance customer experience and drive conversions, with a phased rollout strategy post-FDA clearance.

This summary encapsulates Tandem Diabetes Care's performance and strategic direction for Q1 2026, highlighting both achievements and challenges as the company navigates a competitive landscape.